FLEMINGTON, N.J., June 24 /PRNewswire/ -- Beardsworth Consulting Group, Inc. announces the appointments of Alison Martin, M.D. as the company’s Scientific Advisor, Oncology and Robert W. Malone, M.D. as the company’s Medical Director, Vaccines.
Dr. Alison Martin is one of oncology’s respected research leaders with over 20 years of clinical research experience. She joins Beardsworth from the National Cancer Institute (NCI) where she was most recently Head of Genitourinary Cancers and Melanoma Therapeutics in the Clinical Investigations Branch of the Cancer Therapy Evaluation Program (CTEP). Dr. Martin was scientific co-chair along with Dr. Meenhard Herlyn of the 2007 NCI-Community-Oriented Strategic Action Plan for Melanoma Research. She has served as liaison to three of NCI’s cooperative groups and been a senior investigator in the Investigational Drug Branch of CTEP. In addition to experience at NCI, Dr. Martin was a team leader in the Office of Oncology Drug Products at the U.S. Food and Drug Administration and has experience working with the biotechnology and pharmaceutical industries.
Dr. Robert Malone has extensive experience in viral and recombinant vaccines, biodefense, gene delivery and transfer, immunology, tissue and cell culture, and DNA vaccination in both the commercial and government market sectors. An internationally recognized scientist, Dr. Malone is known as one of the original inventors of “DNA Vaccination” holding numerous fundamental domestic & foreign patents in the fields of gene delivery, delivery formulations, and vaccines. His background includes over 25 years of experience in academia and industry, including both founding and working with a wide range of pharmaceutical and biotech companies. He has experience in federal contracting, working with NGO’s in health related research and development as well as relationships with CDC, DOD and HHS. Dr. Malone is involved with 15 issued patents, has numerous publications and two book chapters in this field, and serves as editor-in-chief of the Journal of Immune Based Therapies and Vaccines.
“We are honored and excited to have Alison and Robert join the Beardsworth team,” said Michael J. O’Brien, President and CEO, Beardsworth. He added, “the increasing demands of Oncology and Vaccine research, individually and together, place Beardsworth in an attractive position given our many years of experience in these two areas. Alison and Robert will provide valuable expertise and vision to the expanding clinical research needs of our growing client base.”
As members of Beardsworth’s team, Drs. Martin and Malone join other noted industry experts whose collective strategic scope and in-depth knowledge support Beardsworth’s mission of delivering superior quality clinical services, on time and on budget.
Headquartered in Flemington, New Jersey, Beardsworth is a privately held contract research organization delivering research and business solutions for clinical research programs since 1986. Focused on complicated trials in complex therapeutic areas, Beardsworth’s clinical team expertise, advanced technology platform, and “Investigator Express” process provide clients with a patient-centric approach to study management, patient recruitment and cost-effective solutions. Beardsworth is a WBENC-certified, woman-owned business and registrant with CCR.
SOURCE Beardsworth Consulting Group, Inc.
